In recent years, identification of VEGF, VEGFR and the mammalian target of rapamycin (mTOR) as dysregulated signaling pathways in the development and progression of RCC has led to the rapid development of novel molecular targeted therapies. Here, KDR is linked to renal cell carcinoma.